Agilent Technologies Inc vs Marvell Technology Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Marvell Technology Inc trades at $218.15 (market cap $187.19B). The key difference: Marvell Technology Inc is far larger — about 4.5× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays the higher dividend (0.69%). Which is the better fit depends on your goals.
| A | MRVL | |
|---|---|---|
Market Cap | $42.00B | $187.19B |
Sector | Health | Technology |
52-Week High | $157.20 | $316.43 |
52-Week Low | $110.24 | $62.31 |
Enterprise Value | $43.55B | $188.63B |
Dividend Yield | 0.69% | 0.12% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
MRVL trades at $218.72, up 3.89% today, with a bullish technical signal from moving averages but neutral oscillators. The stock has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $0.928. Revenue grew to $5.77B in 2025, though net income was negative. Analyst consensus is strongly bullish with an 82% buy rating and a $275.68 price target, implying 26% upside. Recent news highlights AI infrastructure product launches and institutional buying interest.
Outlook is positive driven by AI growth and earnings momentum, but high valuation multiples (P/E 75.16) and geopolitical risks from U.S.-China trade tensions pose challenges. Cash flow trends show improvement, with 2026 net cash flow projected at $3.0B. Investors should weigh strong analyst support against margin pressures and competitive threats in the semiconductor sector.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →